Finch Therapeutics to Participate in Upcoming Investor Conferences
Finch Therapeutics (Nasdaq: FNCH) announced CEO Mark Smith will participate in two virtual investor conferences. The first is the Jefferies London Healthcare Conference, featuring a pre-recorded fireside chat available on November 18, 2021. The second is the Evercore ISI 4th Annual HealthCONx Conference, with a fireside chat on December 2, 2021. Both webcasts will be archived on Finch's website for approximately 30 days. Finch is focused on microbiome therapeutics, with its lead candidate, CP101, in late-stage development for recurrent C. difficile infection.
- None.
- None.
SOMERVILLE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate virtually in two upcoming investor conferences:
- Jefferies London Healthcare Conference: Finch will participate in a pre-recorded fireside chat that will be available beginning on Thursday, November 18, 2021 at 3:00 am ET.
- Evercore ISI 4th Annual HealthCONx Conference: Finch will participate in a fireside chat on Thursday, December 2, 2021 at 10:05 am ET.
Webcasts of both fireside chats will be available under the ‘Investors & News’ section of the Finch website and will be archived for approximately 30 days.
About Finch Therapeutics
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. PRISM4, a Phase 3 trial, is designed to serve as the second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. Finch has a partnership with Takeda focused on the development of targeted microbiome therapeutics for inflammatory bowel disease.
Human-First Discovery® is a registered trademark of Finch Therapeutics Group, Inc.
Investor Contact:
Laurence Watts
Gilmartin Group
(619) 916-7620
laurence@gilmartinir.com
or
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
Berry & Company Public Relations
jurban@berrypr.com
212-253-8881
FAQ
When will Finch Therapeutics participate in the Jefferies London Healthcare Conference?
What is the date for Finch Therapeutics' participation in the Evercore ISI Conference?
Where can I find the webcasts of Finch Therapeutics' investor conferences?
What is the main focus of Finch Therapeutics?
What recent designations has CP101 received?
